References
HNSCC, head and neck squamous-cell carcinoma (HNSCC).•, head and neck cancer.•
Papers of special note have been highlighted as: • of interest• Led to US FDA approval of single-agent nivolumab for second-line palliative therapy of advanced, recurrent or metastatic (A/R/M) head and neck squamous-cell carcinoma (HNSCC).• Led to FDA approval of pembrolizumab for second-line palliative therapy of A/R/M HNSCC.• Led to FDA approval of pembrolizumab for use as a single agent or in combination with chemotherapy in first-line therapy of A/R/M HNSCC.• Led to FDA approval of PD-L1 IHC 22C3 pharmDx for use as an aid in identifying HNSCC patients for treatment with pembrolizumab.• Detailed review of palliative radiotherapy (RT) for head and neck cancer.• Comprehensive review of immunosensitizing effect of and treatment results with RT given concurrently with immunotherapy with immune checkpoint inhibitors in A/R/M HNSCC.